Anlotinib in Combination with Metronomic Chemotherapy in HER2-negative Metastatic Breast Cancer: an Observational and Retrospective Study

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2025 Jan 3

PMID 39754078

Authors

Jiaxuan Liu

Jiayang Zhang

Huiping Li

Guohong Song

Lijun Di

Hanfang Jiang

Ying Yan

Huan Wang

Jing Wang

Xiaoran Liu

Bin Shao

Qiao Li

Affiliations

Soon will be listed here.

Abstract

Anti-angiogenesis offers an important treatment strategy for metastatic breast cancer (MBC). Metronomic chemotherapy (MCT) provides antiangiogenic effects without increased toxicities, making it good partner for antiangiogenic therapy. We conducted the present retrospective study to evaluate the efficacy and safety of anlotinib plus MCT for HER2 negative MBC. Patients with HER2 negative MBC who received metronomic chemotherapy (Vinorelbine (NVB), Capecitabine (CAPE), Etoposide (VP-16)) with anlotinib were retrospectively analyzed from Jan 2019 to Dec 2021. The primary end point was progression free survival (PFS). Secondary end points included objective response rate (ORR), disease control rate (DCR), overall survival (OS) and safety. 48 patients with HER2 negative MBC were enrolled. 19 (39.6%) patients received NVB, 17 (35.4%) patients received CAPE and 12 (25.0%) patients received VP-16. The overall ORR and DCR were 8.3% (4/48) and 87.5% (42/48) respectively. The median PFS was 5.6 months (95% CI 4.3-7.0 months), and the median OS was 25.2 months (95% CI 20.2-30.1 months). The patients with age ≥ 50 (5.3 vs. 7.7 months, P = 0.014, HR = 0.407) and pathologic grade 1 or 2 (6.2 vs. 3.2 months, P = 0.023, HR = 2.471) had significantly longer PFS. The patients with hormone receptor (HR) positive (5.3 vs. 7.7 months, P = 0.004, HR = 0.206) and pathologic grade 1 or 2 (6.2 vs. 3.2 months, P = 0.020, HR = 3.882) had significantly longer OS. The incidence of all grades adverse events (AEs) was 56.3% (27/48) and grade 3-4 AEs was 12.5% (6/48). Within the context of real-world clinical practice, anlotinib in combination with metronomic chemotherapy provides a well-tolerated and effective treatment option for HER2-negative MBC, which warrants further investigation in the future.

References

Cazzaniga M, Pinotti G, Montagna E, Amoroso D, Berardi R, Butera A . Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study. Breast. 2019; 48:7-16. DOI: 10.1016/j.breast.2019.07.006. View

Javed Ansari M, Bokov D, Markov A, Turki Jalil A, Shalaby M, Suksatan W . Cancer combination therapies by angiogenesis inhibitors; a comprehensive review. Cell Commun Signal. 2022; 20(1):49. PMC: 8991477. DOI: 10.1186/s12964-022-00838-y. View

Saji S, Taira N, Kitada M, Takano T, Takada M, Ohtake T . Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial. Lancet Oncol. 2022; 23(5):636-649. DOI: 10.1016/S1470-2045(22)00196-6. View

Goetz M, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J . MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017; 35(32):3638-3646. DOI: 10.1200/JCO.2017.75.6155. View

Lu Y, Im S, Colleoni M, Franke F, Bardia A, Cardoso F . Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. Clin Cancer Res. 2021; 28(5):851-859. PMC: 9377723. DOI: 10.1158/1078-0432.CCR-21-3032. View

Hanahan D, Bergers G, Bergsland E . Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000; 105(8):1045-7. PMC: 300842. DOI: 10.1172/JCI9872. View

Montagna E, Cancello G, Bagnardi V, Pastrello D, Dellapasqua S, Perri G . Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity. Clin Breast Cancer. 2012; 12(3):207-14. DOI: 10.1016/j.clbc.2012.03.008. View

Nie C, Lv H, Xing Y, Chen B, Xu W, Wang J . The efficacy and safety of apatinib treatment for patients with advanced or recurrent biliary tract cancer: a retrospective study. BMC Cancer. 2021; 21(1):189. PMC: 7903638. DOI: 10.1186/s12885-021-07907-4. View

Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro M, Andre F . 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020; 31(12):1623-1649. PMC: 7510449. DOI: 10.1016/j.annonc.2020.09.010. View

10.

Rochlitz C, Bigler M, Von Moos R, Bernhard J, Matter-Walstra K, Wicki A . SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase.... BMC Cancer. 2016; 16(1):780. PMC: 5057418. DOI: 10.1186/s12885-016-2823-y. View

11.

Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R . Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol. 2008; 26(30):4899-905. DOI: 10.1200/JCO.2008.17.4789. View

12.

Cristofanilli M, Turner N, Bondarenko I, Ro J, Im S, Masuda N . Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre,.... Lancet Oncol. 2016; 17(4):425-439. DOI: 10.1016/S1470-2045(15)00613-0. View

13.

Liu S, Zhi W, Zhang L . Efficacy of anlotinib in Chinese patients with metastatic breast cancer: A retrospective observational study. J Cell Mol Med. 2023; 28(5):e18008. PMC: 10902571. DOI: 10.1111/jcmm.18008. View

14.

Kerbel R, Kamen B . The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004; 4(6):423-36. DOI: 10.1038/nrc1369. View

15.

Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F . Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol. 2016; 3(2):194-201. PMC: 7505121. DOI: 10.1001/jamaoncol.2016.3797. View

16.

Sun Z, Lan X, Xu S, Li S, Xi Y . Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis. BMC Cancer. 2020; 20(1):180. PMC: 7057674. DOI: 10.1186/s12885-020-6674-1. View

17.

van Rossum A, Mandjes I, van Werkhoven E, van Tinteren H, van Leeuwen-Stok A, Nederlof P . Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01). Breast Care (Basel). 2022; 16(6):598-606. PMC: 8740214. DOI: 10.1159/000512200. View

18.

Mayer E, Isakoff S, Klement G, Downing S, Chen W, Hannagan K . Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics. Breast Cancer Res Treat. 2012; 136(1):169-78. PMC: 5472381. DOI: 10.1007/s10549-012-2256-5. View

19.

Li Z, Guo F, Han Y, Wang J, Xu B . Efficacy and Safety of Bevacizumab in Pretreated Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. Oncol Res Treat. 2022; 45(10):608-617. PMC: 9677857. DOI: 10.1159/000525882. View

20.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View